Can the survival curves printed in decades of small DIPG (diffuse intrinsic pontine glioma) trials be turned back into approximate patient-level data and pooled into one open, shared control group, so that the field can see whether any added treatment ever beat radiotherapy alone and can judge new single-arm trials against a fair benchmark?
- Good it would do
- 2 / 5
- Can AI help
- 3 / 5
- How neglected
- 4 / 5
- Can we check it
- 3 / 5
Why we stopped
Reject. The headline question (did any added treatment ever beat radiotherapy alone in DIPG?) has been asked repeatedly with the answer no, and rebuilt survival curves cannot answer it causally; the benchmark half is already served by registries holding patient-level data (SIOPE registry, radiotherapy-only median 10.4 months), which the FDA's draft guidance expects, and the rebuilding method is already in use in this disease (2026). Good done 2. The outside skeptic argued for Park; a narrower meta-research question (how variable are single-arm results under no effect) is recorded for the scout.
Why it's stuck
DIPG trials are small, mostly single-arm and very varied, so they are rarely pooled properly. A 2017 systematic review and meta-analysis of 65 studies (Hassan and others, Journal of Neuro-Oncology) said 'Meta-analyses of median overall survival results was not possible due to the lack of reported measures of variance' and that it 'is limited by the lack of adequate reporting of censored and missing participants'.
What we'd try
Find every DIPG and diffuse midline glioma trial and cohort that printed a Kaplan-Meier survival curve. Digitise the curves at scale with automated figure extraction checked by a second pass.
Think we got it wrong?
Ruled-out problems can come back. Tell us what we missed.
Members can read the full record for this problem, check its sources and comment. Open the member view → Not a member? Here is how to join.